Intravenous iron supplementation in the anaemia of renal and cardiac failure - A double-edged sword?

Nephrology Dialysis Transplantation

Volumn 20, Issue SUPPL. 7, 2005, Pages

  Slotki, Itzchak ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Anaemia; Cardiac failure; End stage renal disease; Intravenous iron; Labile plasma iron; Oxidative stress

Indexed keywords

FREE RADICAL; HEPCIDIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; ATHEROSCLEROSIS; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; HEART FAILURE; HUMAN; INFECTION RISK; INFLAMMATION; IRON METABOLISM; IRON OVERLOAD; IRON THERAPY; KIDNEY FAILURE; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT;

ANEMIA; HEART FAILURE; HEMATINICS; HUMANS; IRON; IRON OVERLOAD; KIDNEY FAILURE; OXIDATIVE STRESS; RISK FACTORS;

EID: 27144435800     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfh1102     Document Type: Article

References (68)

1. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001; 16 [Suppl 7]: 25-28
2. Kooistra MP, Marx JJ. The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients. Nephrol Dial Transplant 1998; 13: 2578-2582
3. Kooistra MP, Niemantsverdriet EC, van Es A et al. Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 1998; 13: 82-88
4. Silverberg DS, Blum M, Agbaria Z et al. Intravenous iron for the treatment of predialysis anemia. Kidney Int Suppl 1999; 69: S79-S85
5. Silverberg DS, Wexler D, Blum M et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int 2001; 21 [Suppl 3]: S236-S240
6. Silverberg DS, Wexler D, Blum M et al. Effect of correction of anemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians. Isr Med Assoc J 2003; 5: 337-339
7. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
8. Adamson JW, Eschbach JW. Erythropoietin for end-stage renal disease. N Engl J Med 1998; 339: 625-627
9. Kaufman JS, Reda DJ, Fye CL et al. Diagnostic value of iron indices in hemodialysis patients receiving epoetin. Kidney Int 2001; 60: 300-308
10. Fishbane S. Safety in iron management. Am J Kidney Dis 2003; 41: 18-26
11. Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis 2003; 41: S80-S83
12. Stenvinkel P, Barany P. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. Nephrol Dial Transplant 2002; 17 [Suppl 5]: 32-37
13. Guerinot ML. Microbial iron transport. Annu Rev Microbiol 1994; 48: 743-772
14. Hoen B. Iron and infection: Clinical experience. Am J Kidney Dis 1999; 34: S30-S34
15. Feldman HI, Santanna J, Guo W et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13: 734-744
16. Stidley C, Sun Y, Harford A et al. Increased mortality in hemodialysis patients receiving no iron and high dose iron therapy. World Congress of Nephrology 2003; abstract
17. Collins A, Ebben J, Ma J, Xia H. I.V. iron dosing patterns and mortality. J Am Soc Nephrol 1998; 9: 205A
18. Collins A, Ma J, Xia H, Ebben J. I.V. iron dosing patterns and morbidity. J Am Soc Nephrol 1998; 9: 204A
19. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-1632
20. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000; 58: 2571-2578
21. Himmelfarb J, McMenamin ME, Loseto G, Heinecke JW. Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 2001; 31: 1163-1169
22. Himmelfarb J. McMonagle E. Manifestations of oxidant stress in uremia. Blood Purif 2001; 19: 200-205
23. Witko-Sarsat V, Friedlander M, Nguyen KT et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532
24. Michelis R, Gery R, Sela S et al. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003; 18: 924-930
25. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N. Induction of protein oxidation by intravenous iron in hemodialysis patients: Role of inflammation. Am J Kidney Dis 2002; 40: 1005-1012
26. Agarwal R, Vasavada N. Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289
27. Drueke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intimamedia thickness in end-stage renal disease. Circulation 2002; 106: 2212-2217
28. Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002; 32 [Suppl 1]: 42-49
29. Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: A quantitative and comparative study. Nephrol Dial Transplant 2004; 19: 561-565
30. Green NS. Yersinia infections in patients with homozygous beta-thalassemia associated with iron overload and its treatment. Pediatr Hematol Oncol 1992; 9: 247-254
31. Boelaert JR, Daneels RF, Schurgers ML et al. Iron overload in haemodialysis patients increases the risk of bacteraemia: A prospective study. Nephrol Dial Transplant 1990: 5: 130-134
32. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Transplant 1995; 10: 377-381
33. Patruta SI, Horl WH. Iron and infection. Kidney Int Suppl 1999; 69: S125-S130
34. Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998: 9: 655-663
35. Deicher R, Ziai F, Cohen G, Mullner M, Horl WH. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003; 64: 728-736
36. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38: 988-991
37. Vanholder R, Van Biesen W, Ringoir S. Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney Int 1993; 44: 208-214
38. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000; 15: 1827-1834
39. Weiss G, Meusburger E, Radacher G et al. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003; 64: 572-578
40. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869-876
41. Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Rapid communication. Kidney Int 2004; 65: 2108-2112
42. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpba, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003; 14: 1776-1784
43. Krause A, Neitz S, Magert HJ et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480: 147-150
44. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810
45. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-788
46. Pigeon C, Ilyin G, Courselaud B et at. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-7819
47. Wessling-Resnick M. A possible link between hepcidin and regulation of dietary iron absorption. Nutr Rev 2002; 60: 371-374
48. Nemeth E, Valore EV, Territo M et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463
49. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-788
50. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093
51. Kulaksiz H, Gehrke SG, Janetzko A et al. Pro-hepcidin: Expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004; 53: 735-743
52. Taes YE, Wuyts B, Boelaert JR, De Vriese AS, Delanghe JR. Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med 2004; 42: 387-389
53. Besarab A, Frinak S, Yee J. An indistinct balance: The safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 1999; 10: 2029-2043
54. Kooistra MP, van Es A, Struyvenberg A, Marx JJ. Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 1991; 79: 634-639
55. Macdougall IC. Strategies for iron supplementation: Oral versus intravenous. Kidney Int Suppl 1999; 69: S61-S66
56. Kernilde J-J, Folkert V, Mockrzycki M. Functional iron deficiency in hemodialysis patients with high ferritin levels. J Am Soc Nephrol 1998; 9: 253A
57. Sunder-Plassmann G, Horl WH. Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1797-1802
58. Zanen AL, Adriaansen HJ, van Bommel EF, Posthuma R, Th de Jong GM. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 820-824
59. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: An abnormal serum iron fraction of potential toxicity. Br J Haematol 1978; 40: 255-263
60. Hershko C, Peto TE. Non-transferrin plasma iron. Br J Haematol 1987; 66: 149-151
61. Batey RG, Lai Chung FP, Shamir S, Sherlock S. A nontransferrin-bound serum iron in idiopathic hemochromatosis. Dig Dis Sci 1980; 25: 340-346
62. Aruoma OI, Bomford A, Polson RJ, Halliwell B. Nontransferrin-bound iron in plasma from hemochromatosis patients: Effect of phlebotomy therapy. Blood 1988; 72: 1416-1419
63. Halliwell B, Aruoma OI, Mufti G, Bomford A. Bleomycin-detectable iron in serum from leukaemic patients before and after chemotherapy. Therapeutic implications for treatment with oxidant-generating drugs. FEBS Lett 1988; 241: 202-204
64. Kooistra MP, Kersting S, Gosriwatana I et al. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002; 32 [Suppl 1]: 36-41
65. Hider RC. Nature of nontransferrin-bound iron. Eur J Clin Invest 2002; 32 [Suppl 1]: 50-54
66. Breuer W, Cabantchik ZI. A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 2001; 299: 194-202
67. Esposito BP, Epsztejn S, Breuer W, Cabantchik ZI. A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal Biochem 2002; 304: 1-18
68. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000; 23: 185-192